Company Profile
Aligos Therapeutics Stock Price, News & Analysis
- Ticker:
- ALGS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
6.36 USD (-3.93%)
Close
Last updated: July 13, 2026 at 00:00
40.97M USD
Market cap
Why the stock is moving
ALGS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aligos Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aligos Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aligos Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aligos Therapeutics (ALGS)?
Aligos Therapeutics (ALGS) most recently closed at 6.36 USD, a -3.93% move versus the previous session.
What is the market cap of Aligos Therapeutics (ALGS)?
Aligos Therapeutics currently has a market capitalization of 40.97M USD on BioPharmSignal.
What does Aligos Therapeutics do?
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ALGS stock listed?
Aligos Therapeutics (ALGS) is associated with NASDAQ, United States, Biotechnology.
What is Aligos?
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Aligos Therapeutics targeting with Aligos?
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Aligos Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.